Blinatumomab: An Investigational BiTE Antibody Construct Designed to Direct the Body’s Cell-destroying T-Cells Against Target Cells Expressing CD19 – Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Blinatumomab - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Blinatumomab is an investigational BiTE antibody construct designed to direct the body's cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blinatumomab is the first of the BiTE antibody constructs and Amgen has received orphan drug designation from the FDA for th